ArticlePakistan journal of medical sciences2025
Effects of Lenvatinib combined with immune checkpoint inhibitors on efficacy, immune function and prognosis in patients with primary liver cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy, immune function effects and safety of lenvatinib combined with immune checkpoint inhibitors (sintilimab) in treating advanced primary liver cancer. Methodology: A retrospective cohort study was conducted on 80 patients with advanced liver cancer in Shijiazhuang People's Hospital from January 2023 to June 2024, who were divided into an observation group (lenvatinib + sintilimab, n=40) and a control group (lenvatinib monotherapy, n=40). Specifically, the overall response rate (ORR), immune function indicators (CD3+, CD4+, CD4+/CD8+, IgM/IgG/IgA), quality of life (SGRQ scores) and adverse reactions were compared between the two groups. Results: The ORR in the observation group (72.5%) was significantly higher than that in the control group (50.0%), with statistically significant differences ( Conclusion: Lenvatinib combined with immune checkpoint inhibitors can significantly improve the objective response rate in patients with advanced liver cancer, enhance their immune function and improve their quality of life, demonstrating satisfactory safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.